PDF factsheet
      Z

New P2Y12 Inhibitors in acute coronary syndrome for all type of patients, clinical trials results

cangrelor up front versus clopidogrel up front
CHAMPION-PCI, 2009
NCT00305162
cangrelor up front (cangrelor administered before percutaneous coronary intervention and followed by clopidogrel)
versus
clopidogrel up front (clopidogrel followed by placebo)
high risk patients requiring PCIdouble blind
Follow-up duration: 48 h
14 countries
cangrelor up front versus delayed clopidogrel
CHAMPION-PLATFORM, 2009
NCT00385138
cangrelor up front (cangrelor during PCI followed by 600 mg of clopidogrel)
versus
delayed clopidogrel (placebo during PCI followed by 600 mg of clopidogrel)
patients with acute coronary syndrome undergoing percutaneous coronary intervention double blind
Follow-up duration: 48 h
18 countries
elinogrel versus placebo
ERASE-MI, 2009
elinogrel 10, 20, 40, or 60 mg as a single intravenous bolus
versus
placebo
STEMI patients double blind
Follow-up duration: 30-37 days
prasugrel versus clopidogrel
JUMBO-TIMI 26, 2005
Prasugrel 3 doses
versus
clopidogrel 300mg loading dose followed by 75 mg daily)
patients undergoing elective or urgent percutaneous coronary interventiondouble blind
Follow-up duration: 30 days
TRITON-TIMI 38, 2007
NCT00097591
prasugrel 60-mg loading dose and 10-mg daily maintenance dose, for 6 to 15 months
versus
clopidogrel (a 300-mg loading dose and a 75-mg daily maintenance dose) for 6 to 15 months
patients with moderate-to-high-risk acute coronary syndromes (UA, NSTEMI,STEMI) with scheduled percutaneous coronary interventiondouble blind
30 countries
ticagrelor versus clopidogrel
PLATO, 2009
NCT00391872
ticagrelor 90mg twice daily
versus
clopidogrel 75mg once daily
patients with an acute coronary syndrome, with or without ST-segment elevation (onset of symptoms within the previous 24h). double blind
Follow-up duration: 1 y
43 countries
DISPERSE-2 (90mg), 2007
ticagrelor 90 mg twice daily
versus
clopidogrel
patients with NSTE-ACS, treated with aspirin and standard therapy for ACSdouble blind
Follow-up duration: 12 weeks

  Options


in first

in second

  Filter